An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients

C. Solaro, G. L. Lunardi, E. Capello, M. Inglese, M. Messmer Uccelli, A. Uccelli, G. L. Mancardi

Research output: Contribution to journalArticlepeer-review

121 Scopus citations

Abstract

We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1). Complete resolution of symptoms or partial improvement was obtained, respectively, in 14 and 4 of 18 patients who ended the study. Sustained improvement with minor side effects was obtained at dosages ranging from 600 to 1200 mg/d. Our findings suggest that GBP may be effective for PS in MS and warrant a further study in a double-blind placebo-controlled trial.

Original languageEnglish
Pages (from-to)609-611
Number of pages3
JournalNeurology
Volume51
Issue number2
DOIs
StatePublished - Aug 1998
Externally publishedYes

Fingerprint

Dive into the research topics of 'An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients'. Together they form a unique fingerprint.

Cite this